Patents Represented by Attorney Lawrence S. Pope
-
Patent number: 6833370Abstract: Heterocyclic substituted aminoazacyclic compounds of formula I Z—R3 I, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.Type: GrantFiled: April 26, 2000Date of Patent: December 21, 2004Assignee: Abbott LaboratoriesInventors: Michael R. Schrimpf, Kevin B. Sippy, Jerome F. Daanen, Keith Brian Ryther, Jianguo Ji
-
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
Patent number: 6437138Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.Type: GrantFiled: March 1, 2000Date of Patent: August 20, 2002Assignee: Abbott LaboratoriesInventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith Ryther, Yihong Li, Hao Bai -
Patent number: 6403575Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.Type: GrantFiled: July 19, 2000Date of Patent: June 11, 2002Assignee: Abbott LaboratoriesInventors: Mark W. Holladay, Stephen P. Arneric, Hao Bai, Michael J. Dart, Nan-Horng Lin, John K. Lynch, Yat Sun Or, Keith B. Ryther, James P. Sullivan, James T. Wasicak, Paul P. Ehrlich
-
Patent number: 6174734Abstract: The invention features a novel method of assaying glycated hemoglobin (GHb) in a sample using a capture molecule that binds GHb and hemoglobin (Hb), and detecting bound GHb with a molecule that distinguishes GHb from non-glycated hemoglobin (Hb). The molecule used to distinguish GHb from Hb may be an antibody. The assay and antibodies of the invention are useful for the evaluation of GHb in disease states such as diabetes.Type: GrantFiled: October 24, 1997Date of Patent: January 16, 2001Assignee: Abbott LaboratoriesInventors: Ralph K. Ito, Gordon Sanghera
-
Patent number: 6166013Abstract: Compounds having Formula I ##STR1## are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.Type: GrantFiled: July 30, 1999Date of Patent: December 26, 2000Assignee: Abbott LaboratoriesInventors: Michael J. Coghlan, Jay R. Luly, Jeffrey M. Schkeryantz, Alan X. Wang
-
Patent number: 6133253Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.Type: GrantFiled: December 9, 1997Date of Patent: October 17, 2000Assignee: Abbott LaboratoriesInventors: Mark W. Holladay, Stephen P. Arneric, Hao Bai, Michael J. Dart, Nan-Horng Lin, John K. Lynch, Yat Sun Or, Keith B. Ryther, James P. Sullivan, James T. Wasicak, Paul P. Ehrlich
-
Patent number: 6133275Abstract: Compounds having the formula are .alpha..sub.1 adrenoreceptor antagonists. Processes for making these compounds, synthetic intermediates employed in these processes and a method for inhibiting .alpha..sub.1 adrenoreceptors and treating benign prostatic hyperplasia (also called benign prostatic hypertrophy or BPH) and other urological diseases such as BOO (bladder outlet obstruction), neurogenic bladder and gynecological syndromes such as dysmenorrhea are disclosed.Type: GrantFiled: May 6, 1998Date of Patent: October 17, 2000Assignee: Abbott LaboratoriesInventors: Paul P. Ehrlich, Jeffrey W. Ralston, Jerome F. Daanen, Michael D. Meyer
-
3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
Patent number: 6127386Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.Type: GrantFiled: April 18, 1997Date of Patent: October 3, 2000Assignee: Abbott LaboratoriesInventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith B. Ryther, Yihong Li, Hao Bai -
Patent number: 6080874Abstract: The present invention provides a simple, 1-step process for preparing a N-(aryl or heteroaryl)-hydroxyurea comprising reacting the corresponding alcohol, ester or ether with hydroxyurea and acid. This reaction is particularly useful for preparing a benzo[b]thienyl substituted N-hydroxyurea of formula: ##STR1## from compound 1: ##STR2## by reacting compound 1 with hydroxyurea and acid. R.sup.1 is selected from the group consisting of hydrogen, 1-6 carbon alkyl, 1-6 carbon alkoxy, and halogen; R.sup.2 is an 1-4 carbon alkyl; and R.sup.3 is selected from the group consisting of hydrogen, acyl, methyl, ethyl and mixtures thereof. Additional steps to isolate the pure bulk product follow.Type: GrantFiled: September 25, 1998Date of Patent: June 27, 2000Assignee: Abbott LaboratoriesInventors: John E. Hengeveld, Elise H. Leese, Brian S. Moon, Dennis M. Abad, Kimberly A. Allen, Philip E. Bauer, David B. Murphey, Brian T. Fohey, Richard R. Copp, Jr., Greg S. Lannoye, Rodney M. Mittag
-
Patent number: 5989827Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.Type: GrantFiled: October 31, 1996Date of Patent: November 23, 1999Assignee: Abbott LaboratoriesInventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
-
Patent number: 5976813Abstract: Continuous format high throughput screening (CF-HTS) using at least one porous matrix allows the pharmaceutical industry to simultaneously screen large numbers of chemical entities for a wide range of biological or biochemical activity. In addition, CF-HTS is useful to perform multi-step assays.Type: GrantFiled: December 12, 1997Date of Patent: November 2, 1999Assignee: Abbott LaboratoriesInventors: Bruce A. Beutel, Mark E. Schurdak, Martin J. Voorbach, David J. Burns, Mary K. Joseph
-
Patent number: 5942632Abstract: A solid phase synthesis method and intermediates useful in the process are disclosed for the preparation of diamino diol and diamino alcohol inhibitors of HIV protease.Type: GrantFiled: July 2, 1998Date of Patent: August 24, 1999Assignee: Abbott LaboratoriesInventor: Gary T. Wang
-
Patent number: 5891643Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.Type: GrantFiled: November 14, 1995Date of Patent: April 6, 1999Assignee: Abbott LaboratoriesInventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
-
Patent number: 5863946Abstract: Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; X is absent or is alkylene; A is absent or is selected from optionally substituted alkylene, optionally substituted cycloalkylene, optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, optionally substituted alkenylene, and ##STR2## or R.sup.2 and A together define a saturated 5- to 8-membered optionally substituted carbocyclic or heterocyclic ring to which the group Z is attached; Z is selected from (a) hydrogen, (b) COM wherein M is selected from the group consisting of --OR.sup.5, a pharmaceutically acceptable cation, --NR.sup.7 R.sup.8, and a pharmaceutically acceptable, metabolically cleavable group, (c) --OR.sup.3, (d) tetrazolyl, (e) --CH(OR.sup.3)--CH.sub.2 OR.sup.9, (f) --CH(OR.sup.3)--CH.sub.2 --CH.sub.2 OR.sup.9, (g) --CH(OR.sup.Type: GrantFiled: June 6, 1996Date of Patent: January 26, 1999Assignee: Abbott LaboratoriesInventors: Clint D. W. Brooks, Richard A. Craig, Teodozyj Kolasa, Andrew O. Stewart
-
Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
Patent number: 5843968Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d) --NR.sup.6 SO.sub.2 R.sup.Type: GrantFiled: October 27, 1997Date of Patent: December 1, 1998Assignee: Abbott LaboratoriesInventors: Clint D. W. Brooks, Pramila Bhatia, Teodozyj Kolasa, Andrew O. Stewart, David E. Gunn, Richard A. Craig -
Patent number: 5811425Abstract: The present invention relates to COX-2 inhibitors of the formula: ##STR1## wherein, A=halogen, C.sub.1 -C.sub.6 alkyl, SR.sup.1 or OR.sup.1 ;B=O, or H,H;X=Br or Cl;L=5-,6- or 7-membered heteroatom containing rings and is preferrably a 5-membered heteroaromatics such as thiazole, oxazole, imidazole, or oxadiazole;n=1-6, wherein the (C) is optionally branched;R=optionally substituted aryl wherein aryl is selected from phenyl, pyridyl, naphthyl, benzothienyl, or quinoxolyl, alkyl, carboxyl, esters, amino, amide, or urea; andR.sup.1 =alkyl. The compounds are useful as research tools and could be useful as potential therapeutic agents in the inhibition of the PGHS-2 isozyme and in the treatment of inflammation in mammals including humans or other conditions associated with the production of prostaglandins.Type: GrantFiled: March 4, 1997Date of Patent: September 22, 1998Assignee: Abbott LaboratoriesInventors: Keith W. Woods, Richard W. McCroskey, Michael R. Michaelides
-
Patent number: 5801119Abstract: A process of inhibiting stem elongation in ornamental bulbous plants or in cut flowers from such plants, involving treating such plants or flowers with an effective amount of ACC synthase inhibitor, such as aminoethoxyvinylglycine and aminooxyacetic acid to inhibit stem elongation, by administration of a solid, semi-solid or a solution of such ACC synthase inhibitor.Type: GrantFiled: December 31, 1996Date of Patent: September 1, 1998Assignee: Abbott LaboratoriesInventors: Gregory D. Venburg, James R. Hansen, Derek D. Woolard, Warren E. Shafer, Candace Black-Schaefer
-
Patent number: 5691456Abstract: Immunoassay methods and reagents for the specific quantification of thyroxine in a test sample are disclosed employing antibodies prepared with thyroxine derivatives of the formula: ##STR1## wherein P is an immunogenic carrier material and X is a linking moiety. The present invention also describes the synthesis of unique labelled reagent of the formula: ##STR2## wherein Q is a detectable moiety and W is a linking moiety, preferably fluorescein or a fluorescein derivative.Type: GrantFiled: May 18, 1995Date of Patent: November 25, 1997Assignee: Abbott LaboratoriesInventors: Maciej Adamczyk, Donald D. Johnson, Phillip G. Mattingly, Diana E. Clarisse, Joan D. Tyner, Mary M. Perkowitz
-
Patent number: 5688921Abstract: Immunoassay methods and reagents for the specific quantification of thyroxine in a test sample are disclosed employing antibodies prepared with thyroxine derivatives of the formula: ##STR1## wherein P is an immunogenic carrier material and X is a linking moiety. The present invention also describes the synthesis of unique labelled reagent of the formula: ##STR2## wherein Q is a detectable moiety and W is a linking moiety, preferably fluorescein or a fluorescein derivative.Type: GrantFiled: May 18, 1995Date of Patent: November 18, 1997Assignee: Abbott Laboratories D-337/AP6DInventors: Maciej Adamczyk, Donald D. Johnson, Phillip G. Mattingly, Diana E. Clarisse, Joan D. Tyner, Mary M. Perkowitz
-
Patent number: D661533Type: GrantFiled: March 28, 2011Date of Patent: June 12, 2012Assignee: InPro CorporationInventors: Matthew G. Bennett, Roger W. Lehrkamp